Graceling

Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit

Retrieved on: 
Thursday, November 16, 2023
SAN, B cell, Cell, Autoimmune disease, SLE, Cancer, Graceling

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing  innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the Company will present at the inaugural Cell Therapy for Autoimmune Disease Summit taking place in Philadelphia and online Nov. 28-30, 2023.

Key Points: 
  • SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing  innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the Company will present at the inaugural Cell Therapy for Autoimmune Disease Summit taking place in Philadelphia and online Nov. 28-30, 2023.
  • Presentation details are as follows:
    Dr. Zhang will present on the application of next-generation CAR-T cell therapies for treatment of autoimmune disease, highlighting insights from Gracell’s development of FasTCAR-enabled CD19/BCMA dual-targeting GC012F in SLE, and the translational research supporting the potential benefit of dual-targeting in maximizing depletion of disease-causing B-cells and plasma cells.

Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Molecule, Multiple myeloma, Webcast, Safety, Research, SAN, Phenotype, ASH, IND, Investment, Exercise, Rejuvenation, SCR, IIT, Patient, CD19, SMART, Indian Institutes of Technology, SLE, TME, Conference, ORR, Cancer, BCMA, Acute lymphoblastic leukemia, Society, Lender option borrower option, Graceling, Pharmaceutical industry, Vaccine, Birth control, Security (finance), Cryptocurrency, Broadcasting

ET today

Key Points: 
  • ET today
    SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today reported third quarter unaudited financial results for the period ended September 30, 2023, and provided corporate updates.
  • We look forward to presenting an update with more details at ASH 2023,” commented Dr. William (Wei) Cao, founder, Chairman and CEO of Gracell.
  • Financial Results for Third Quarter Ended September 30, 2023
    As of September 30, 2023, the Company had RMB1,707.9 million (US$234.1 million) in cash and cash equivalents and short-term investments.
  • Interest income for the three months ended September 30, 2023 was RMB9.9 million (US$1.4 million), compared to RMB3.6 million for the corresponding prior year period.

Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program

Retrieved on: 
Wednesday, November 8, 2023
IIT, Bone marrow, Multiple myeloma, SCR, Graceling, Immunotherapy, Autoimmune disease, Cancer, Patient, Biotechnology, SAN, Pharmaceutical industry

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that Gracell’s FasTCAR-T GC012F was selected as the winner of BioTech Breakthrough’s Overall Immunology Solution of the Year award.

Key Points: 
  • Since its founding, Gracell has been developing a rich pipeline of transformational CAR-T therapies, aiming to broaden the use of breakthrough cell therapies across hematological malignancies, solid tumors and autoimmune conditions.
  • GC012F, developed with Gracell’s revolutionary next-day autologous CAR-T cell manufacturing platform, FasTCAR, is a CAR-T therapy candidate that stands to transform cancer and autoimmune treatment.
  • Additional positive data has recently been announced from studies evaluating GC012F for the treatment of relapsed/refractory multiple myeloma (rrMM) and B-cell non-Hodgkin’s lymphoma (B-NHL).
  • The BioTech Breakthrough Awards program was founded in 2021 by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 1, 2023
News, Graceling, Cancer, Webcast, Autoimmune disease, SAN, Pharmaceutical industry, Broadcasting

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the management team will participate in four upcoming investor conferences in November.

Key Points: 
  • SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the management team will participate in four upcoming investor conferences in November.
  • Available webcasts of the presentations will be posted on the News and Events section of the Company's website.
  • A replay of the webcast will be available for 90 days following the event.
  • For more information, please visit ir.gracellbio.com .

Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
IIT, Research, Society for Immunotherapy of Cancer, Research and development, Poster, Graceling, SITC, Immunotherapy, SMART, Annual general meeting, Autoimmune disease, Tumor microenvironment, Society, Cancer, TME, Apoptosis, SAN, Vaccine, TGF

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, announced today preclinical data from the Company’s SMART CART™* technology for solid tumors will be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 1-5, 2023, in San Diego and online.

Key Points: 
  • “Gracell has long been dedicated to unlocking the tremendous potential of CAR-T therapy against solid tumors in our pursuit of transformative cell therapies.
  • We are thrilled to present the encouraging preclinical data from SMART CART, our next-generation solid tumor technology,” said Dr. Lianjun Shen, Gracell’s Senior Vice President, Head of Research & Development.
  • “Immunosuppressive tumor microenvironment is a known challenge that limits CAR-T cell proliferation and persistence, and, ultimately, its effectiveness against solid tumors.
  • We believe our research to be presented at SITC demonstrates SMART CART’s improved resistance to TME and superior in vitro and in vivo preclinical efficacy.

Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate

Retrieved on: 
Wednesday, September 27, 2023
IIT, ASH, CD19, SCR, International, CRS, Multiple myeloma, DOR, B-cell maturation antigen, Cancer, MRD, Cytokine release syndrome, Patient, Graceling, IMS, Autoimmune disease, Poster, Rollcage Stage II, Society, III, ORR, BCMA, Safety, Grade 2, Vaccine, Pharmaceutical industry, Medical device, Hematology

The abstract (P-136) was presented as a poster at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece.

Key Points: 
  • The abstract (P-136) was presented as a poster at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece.
  • GC012F demonstrated a 100% overall response rate (ORR) and a 100% MRD- sCR rate among 19 transplant-eligible, high-risk NDMM patients as of the data cutoff date of August 1, 2023.
  • The data also showed that GC012F was well-tolerated with no new safety signals observed in this frontline application of CAR-T therapy.
  • We are delighted to report that in this study, all 19 NDMM patients treated by GC012F achieved MRD- sCR with favorable safety.

Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Tuesday, September 26, 2023
IIT, CD19, European Hematology Association, Multiple myeloma, Survival, Cancer, Pharmacokinetics, Trial of the century, ASCO, American Society of Clinical Oncology, Patient, Graceling, SAN, Autoimmune disease, EHA, RRMM, Society, Neurotoxicity, ORR, BCMA, Safety, Pharmaceutical industry, Medical device

The Phase 1b portion of the open-label multi-center trial has been initiated and will be conducted at several top medical centers in the United States.

Key Points: 
  • The Phase 1b portion of the open-label multi-center trial has been initiated and will be conducted at several top medical centers in the United States.
  • The Phase 2 portion is intended to evaluate the efficacy of GC012F in RRMM patients and further characterize the safety of GC012F.
  • “Gracell has amassed a body of compelling evidence supporting the dual-targeting approach of GC012F for treatment of RRMM.
  • “Dosing the first patient in the Phase 1b portion of the U.S. trial is another important step toward validating this treatment for RRMM patients.

Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders

Retrieved on: 
Tuesday, September 19, 2023
IIT, Drug development, Multiple myeloma, Cancer, EDT, Sutro Biopharma, Patient, Graceling, SAN, Autoimmune disease, Industry Dive, BCMA, Bone marrow, Pharmaceutical industry, RRMM

“I am deeply honored and humbled to receive recognition from our industry’s most prominent leaders,” Dr. Cao said.

Key Points: 
  • “I am deeply honored and humbled to receive recognition from our industry’s most prominent leaders,” Dr. Cao said.
  • With more than 30 years of experience in the life science industry, Dr. Cao has led Gracell since its founding in 2017.
  • In 2022, FasTCAR was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Award for its potential to address major industry obstacles.
  • The event will bring together newsmaking leaders from across pharma and biotech for keynote presentations, panels and fireside chats.

Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
Janus, Exercise, Lender option borrower option, IIT, RA, CD19, SCR, HLA, OrbiMed, DLBCL, ADS, Multiple myeloma, Cancer, Research, Commencement at Central Connecticut State University, ASCO, Patient, Investment, Graceling, B-ALL, SAN, TME, EHA, Webcast, BCMA, RRMM, SMART, ORR, Conference, Pharmaceutical industry, Security (finance), Vaccine, Cryptocurrency, Broadcasting

ET today

Key Points: 
  • ET today
    SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today reported second quarter unaudited financial results for the period ended June 30, 2023, and provided corporate updates.
  • “We are delighted with the significant milestones achieved in the past few months across our reprioritized pipeline.
  • The Phase 1b part of the RRMM US IND trial has commenced as patient screening is underway.
  • Financial Results for Second Quarter Ended June 30, 2023
    As of June 30, 2023, the Company had RMB1,188.0 million (US$163.8 million) in cash and cash equivalents and short-term investments.

Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference

Retrieved on: 
Monday, July 31, 2023
SAN, Cancer, ET, Conference, Graceling, Pharmaceutical industry, Cryptocurrency

SAN DIEGO and SUZHOU and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate in the BTIG Virtual Biotechnology Conference on August 7 - 8.

Key Points: 
  • SAN DIEGO and SUZHOU and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate in the BTIG Virtual Biotechnology Conference on August 7 - 8.
  • The Gracell team is scheduled to present on August 8th at 11:00 am ET and will host investor meetings at the conference on August 7-8.